Enhanced Safety and Efficacy of Oncolytic VSV Therapy by Combination with T Cell Receptor Transgenic T Cells as Carriers

Vesicular stomatitis virus (VSV) represents an attractive oncolytic virotherapy platform because of its potent tumor cell-killing and immune-stimulating properties; yet the clinical translation of VSV faces numerous challenges, such as inefficient systemic delivery and severe side effects such as ne...

Descripción completa

Detalles Bibliográficos
Autores principales: Melzer, Michael Karl, Zeitlinger, Lisa, Mall, Sabine, Steiger, Katja, Schmid, Roland M., Ebert, Oliver, Krackhardt, Angela, Altomonte, Jennifer
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Gene & Cell Therapy 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6325079/
https://www.ncbi.nlm.nih.gov/pubmed/30662938
http://dx.doi.org/10.1016/j.omto.2018.12.001

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6325079/
https://www.ncbi.nlm.nih.gov/pubmed/30662938
http://dx.doi.org/10.1016/j.omto.2018.12.001

Ejemplares similares